Multifunctional nanomedicines-enabled chemodynamic-synergized multimodal tumor therapy via Fenton and Fenton-like reactions

Theranostics, Journal Year: 2023, Volume and Issue: 13(6), P. 1974 - 2014

Published: Jan. 1, 2023

Chemodynamic therapy (CDT) is well-known for using the tumor microenvironment to activate Fenton reaction or Fenton-like generate strong oxidative hydroxyl radicals tumor-specific treatment. It highly selective and safe, without depth limitation of tissue penetration, shows its potential as a new green therapeutic method with great clinical application. However, catalytic efficiency reagents involved in severely affected by inherent microenvironmental limitations tumors strict reaction-dependent conditions. With increasing application nanotechnology medical field, combined therapies based on different types functional nanomaterials have opened up avenues development next-generation CDT-enhanced system. This review will comprehensively exemplify representative results CDT other antitumor such chemotherapy, phototherapy, sonodynamic therapy, radiation magnetic hyperthermia immunotherapy, starvation gas gene oncosis combination thereof improving from hundreds latest literature, introduce strategies ingenious design nanomedicines regulations enhance further summarize challenges future perspective CDT-based multimodal anticancer therapy.

Language: Английский

---

The next frontier in immunotherapy: potential and challenges of CAR-macrophages

Experimental Hematology and Oncology, Journal Year: 2024, Volume and Issue: 13(1)

Published: Aug. 5, 2024

Abstract Chimeric antigen receptor macrophage (CAR-MΦ) represents a significant advancement in immunotherapy, especially for treating solid tumors where traditional CAR-T therapies face limitations. CAR-MΦ offers promising approach to target and eradicate tumor cells by utilizing macrophages’ phagocytic antigen-presenting abilities. However, challenges such as the complex microenvironment (TME), variability expression, immune suppression limit their efficacy. This review addresses these issues, exploring mechanisms of action, optimal construct designs, interactions within TME. It also delves into ex vivo manufacturing CAR-MΦ, discussing autologous allogeneic sources importance stringent quality control. The potential synergies integrating with existing cancer like checkpoint inhibitors conventional chemotherapeutics are examined highlight possible enhanced treatment outcomes. Furthermore, regulatory pathways scrutinized alongside established protocols cells, identifying unique considerations essential clinical trials market approval. Proposed safety monitoring frameworks aim manage adverse events, cytokine release syndrome, crucial patient safety. Consolidating current research insights, this seeks refine therapeutic applications, overcome barriers, suggest future directions transition from experimental platforms standard care options.

Language: Английский

---

Emerging Strategies to Overcome Current CAR-T Therapy Dilemmas - Exosomes Derived from CAR-T Cells

International Journal of Nanomedicine, Journal Year: 2024, Volume and Issue: Volume 19, P. 2773 - 2791

Published: March 1, 2024

Abstract: Adoptive T cells immunotherapy, specifically chimeric antigen receptor (CAR-T), has shown promising therapeutic efficacy in the treatment of hematologic malignancies. As extensive research on CAR-T therapies been conducted, various challenges have emerged that significantly hampered their clinical application, including tumor recurrence, cell exhaustion, and cytokine release syndrome (CRS). To overcome hurdles therapy treatment, cell-free emerging based exosomes derived from developed as an effective alternative approach. In this review, we present cell-based for tumors, features benefits therapies, limitations exist field, measures taken to them. Furthermore, discuss notable utilizing released anticipate potential issues trials. Lastly, drawing previous characteristics exosomes, propose strategies these restrictions. Additionally, review discusses plight large-scale preparation exosome provides solutions future applications. Keywords: tumor, cells, immune escape,

Language: Английский

---

Molecular alterations of driver genes in non-small cell lung cancer: from diagnostics to targeted therapy.

PubMed, Journal Year: 2023, Volume and Issue: 22, P. 415 - 432

Published: Jan. 1, 2023

Lung cancer is the leading cause of death all over world. The majority (80-85 %) lung cases are classified as non-small cell (NSCLC). Within NSCLC, adenocarcinoma (AC) and squamous carcinoma (SCC) most often recognized. histological immunohistochemical examination NSCLC a basic diagnostic tool, but insufficient for comprehensive therapeutic decisions. In some patients, mainly adenocarcinoma, molecular alterations in driver genes, like EGFR, KRAS, HER2, ALK, MET, BRAF, RET,ROS1, NTRK frequency those changes different depending on race, between smokers non-smokers. diagnostics using modern methods, next-generation sequencing, essential estimating targeted, personalized therapy. recent years, breakthrough understanding importance studies precise treatment has been observed. Many new drugs were approved, including tyrosine kinase immune checkpoint inhibitors. Clinical trials testing novel molecules miRNAs with CAR-T cells (chimeric antigen receptor - T cells) dedicated to patients ongoing.

Language: Английский

---

Highly proliferative and hypodifferentiated CAR-T cells targeting B7–H3 enhance antitumor activity against ovarian and triple-negative breast cancers

Cancer Letters, Journal Year: 2023, Volume and Issue: 572, P. 216355 - 216355

Published: Aug. 18, 2023

Language: Английский

---

Efficient combination of radiotherapy and CAR-T – A systematic review

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 174, P. 116532 - 116532

Published: April 3, 2024

Chimeric antigen receptor T (CAR-T) cell therapy, a groundbreaking immunotherapy. However, it faces formidable challenges in treating solid tumors, grappling with issues like poor trafficking, limited penetration, and insufficient persistence within the tumor microenvironment (TME). CAR-T cells are engineered to express receptors that target specific cancer antigens, enhancing their ability recognize eliminate cells. This review paper explores intricate interplay between therapy radiotherapy (RT), investigating synergistic potential. Radiotherapy, standard treatment, involves using high doses of radiation damage cells, disrupting grow divide. We highlight RT modulates TME, augments presentation, promotes immune infiltration, bolstering cell-mediated eradication. Molecular insights shed light on RT-induced alterations stroma, recruitment promotion, induction immunogenic death. Noteworthy, strategies, such as combining hypofractionated myeloid-derived suppressor blockade, underscore innovative approaches enhance tumors. Bridging indications for hematological malignancies discussed, emphasizing scenarios where strategically enhances efficacy. The critically evaluates bridge compared traditional chemotherapy, highlighting timing dosage considerations crucial optimizing outcomes. In summary, provides valuable into molecular mechanisms activated by strategies improve fostering deeper understanding combined potential treatment.

Language: Английский

---

CAR-T cell-derived exosomes: a new perspective for cancer therapy

Stem Cell Research & Therapy, Journal Year: 2024, Volume and Issue: 15(1)

Published: June 18, 2024

Abstract Chimeric antigen receptor (CAR)-T cell adoptive immunotherapy is a promising cancer treatment that uses genetically engineered T cells to attack tumors. However, this therapy can have some adverse effects. CAR-T cell-derived exosomes are potential alternative may overcome limitations. Exosomes small vesicles released by and carry variety of molecules, including proteins, RNA, DNA. They play an important role in intercellular communication be used deliver therapeutic agents cells. The application could make more clinically controllable effective. cell-free, which means they less likely cause reactions than combination effective way treat either alone. where cannot reach. appropriate both cellular exosomal platforms practicable for cancer. This offer safe cancers.

Language: Английский

---

Application of novel CAR technologies to improve treatment of autoimmune disease

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Oct. 9, 2024

Chimeric antigen receptor (CAR) T cell therapy has become an important treatment for hematological cancers, and its success spurred research into CAR therapies other diseases, including solid tumor cancers autoimmune diseases. Notably, the development of CAR-based treatments diseases shown great progress recently. Clinical trials anti-CD19 anti-BCMA cells in treating severe B cell-mediated like systemic lupus erythematosus (SLE), have lasting remission thus far. targeting autoreactive are beginning clinical mediated autoantigen (CAAR) specifically target eliminate only cells, they promise mucosal pemphigus vulgaris MuSK myasthenia gravis. Regulatory also been developed, which show potential altering affected areas by creating a protective barrier as well helping decrease inflammation. These new applications disease. Novel technologies developed that increase safety, potency, specificity, efficacy therapy. Applying these novel modifications to CARs enhance applicability This review will detail several recently discuss how their application disease improve this emerging field. include logic-gated CARs, soluble protein-secreting modular enable be more specific, reach wider span safer patients, give potent cytotoxic response. revolutionize growing therapies.

Language: Английский

---

Immunomodulatory drugs: a promising clinical ally for cancer immunotherapy

Trends in Molecular Medicine, Journal Year: 2024, Volume and Issue: 30(8), P. 765 - 780

Published: May 30, 2024

Language: Английский

---

Are immunosenescent T cells really senescent?

Aging Cell, Journal Year: 2024, Volume and Issue: 23(10)

Published: Aug. 7, 2024

Abstract Loss of proper T‐cell functioning is a feature aging that increases the risk developing chronic diseases. In aged individuals, highly differentiated T cells arise with reduced expression CD28 and CD27 an increased KLRG‐1 or CD57. These are often referred to as immunosenescent but may still be active contribute autoimmunity. Another population known exhausted arises after antigen stimulation loses its effector functions, leading failure combat malignancies viral infections. A process called cellular senescence also during aging, targeting this has proven fruitful against range age‐related pathologies in animal models. Cellular occurs irreparably damaged, limiting their proliferation typically secretion pro‐inflammatory factors. To develop therapies caused by defective function, it important understand differences similarities between immunosenescence senescence. Here, we review hallmarks versus senescent provide considerations for development specific

Language: Английский

---